Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
420 participants in 11 patient groups
Loading...
Central trial contact
Reference Study ID Number: GO39775 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal